@article{959d10bd4e604a48818968b119591710,
title = "Meeting Report of the XIV International Small Bowel Transplant Symposium: Summary of Presentations, Workshops, and Debates From a Comprehensive Meeting on Intestinal Failure, Rehabilitation, and Transplantation, Buenos Aires, Argentina, June 10–13, 2015",
abstract = "The 2015 meeting of the Intestinal Transplant Association was held in Buenos Aires, Argentina. This was the 14th International Small Bowel Transplant Symposium, and it was the first meeting organized as a joint venture of the Transplantation Society, the Intestinal Transplant Association, and the Argentinean Transplant Society (Sociedad Argentina de Trasplantes). Innovative aspects of the classic meeting format included workshops sessions, debates, and multicenter studies. This report highlights the most prominent scientific contributions and results of the first such symposium in a Latin American country.",
keywords = "debates, immunosupression, intestinal transplant, liver disease, meeting report, nutrition support practice, rehabilitation, surgical techniques, venous access, workshops",
author = "Gondolesi, {Gabriel E.} and Adriana Fernandez and Burghardt, {Karolina M.} and Scott Nowakowski and Kaufman, {Stuart S.} and Andreas Pascher and Diana Florescu and Phillip Ruiz and Rodrigo Vianna and Sara Clarke and Mihai Oltean and Martin Rumbo and George Mazariegos and Sudan, {Debra L.} and Farmer, {Douglas G.}",
note = "Funding Information: Medical intestinal rehabilitation recently acquired another valuable therapeutic option when the intestinotrophic agent—the recombinant glucagon-like peptide 2 (GLP-2) teduglutide (Gattex; Shire Pharmaceuticals), which works by promoting mucosal growth and restoring gastric emptying and secretion—was introduced as a new pharmacologic alternative. The early promising results were supported by several abstract presentations during this symposium, and its use has been extended worldwide. New results from the phase III extension study—an open-label, multicenter, multinational study, the primary end point of which was to have 20% reduction in weekly parenteral support (PS) volume from baseline to weeks 20 and 24—suggests that GLP-2 achieves similar efficacy among patients with short bowel syndrome with a variety of remnant bowel anatomy, including ultrashort remnant bowel, and/or those with lack of colonic continuity. Independence from PS was achieved after 1 year of therapy, suggesting an accrued and safe benefit with long-term use of GLP-2.15-17 Publisher Copyright: {\textcopyright} 2017 American Society for Parenteral and Enteral Nutrition",
year = "2018",
month = feb,
doi = "10.1177/0148607117701696",
language = "English (US)",
volume = "42",
pages = "477--489",
journal = "Journal of Parenteral and Enteral Nutrition",
issn = "0148-6071",
publisher = "SAGE Publications Inc.",
number = "2",
}